What is solid-phase peptide synthesis?

Solid-phase peptide synthesis (SPPS) is a chemical method for constructing peptides by sequentially adding amino acids to a growing chain that is anchored to an insoluble polymer support. The formal name is solid-phase peptide synthesis; it is also referred to as solid-phase synthesis or SPPS. The method belongs to the class of solid-supported synthesis techniques. Identifiers such as sequence, formula, or molecular weight are not applicable to the method itself, but specific peptides produced by SPPS have defined sequences; for example, the human cathelicidin LL-37 is a 37-residue peptide with a net charge of +6 [1].

The work in this area centres on the chemistry of peptide bond formation and the properties of the solid support, rather than on a single receptor family or pathway.

Research Studies

LL-37 and its functional profile after modification with 2,3-diaminopropionic acid and an oxa-acid spacer

In a study on human cathelicidin LL-37, researchers modified the peptide with 2,3-diaminopropionic acid functionalized with an oxa-acid spacer. The native LL-37 couples broad-spectrum antimicrobial activity with immunomodulatory function, but its therapeutic use is limited by rapid proteolysis and peptidylarginine deiminase (PAD)-mediated citrullination. The modified peptides were evaluated for enzymatic stability and effects on neutrophil degranulation. The study reported enhanced enzymatic stability and selective suppression of neutrophil degranulation in the modified peptides compared to the native sequence [1]. This finding was observed in in vitro assays; no animal or human data were reported in the evidence block.

D-Amino acids in FDA-approved peptide drugs

A historical and developmental perspective on FDA-approved drugs containing D-amino acids reported that D-amino acids, the non-natural enantiomers of L-amino acids, have been used in peptide drug development. Their resistance to proteolytic degradation, enhanced conformational rigidity, and reduced immunogenicity make them valuable in designing long-acting peptides. The review covered approved drugs and their development, but the evidence block does not provide specific numbers or comparative data [2]. This is a review of existing drugs; no new experimental data were presented.

Silica-assisted solid-phase peptide synthesis (SiPPS) and coupling time

In a study on silica-assisted solid-phase peptide synthesis (SiPPS), a non-swelling silica-based resin was used for peptide synthesis. The strategy is similar to that of conventional SPPS. The researchers compared coupling times and found that a 2-hour coupling seemed to favour the coupling compared to a 1-hour standard coupling. The use of this non-swelling resin was explored for its potential advantages in synthesis [3]. This work was performed in a laboratory setting; no biological testing in animals or humans was reported.

Comparison of SPPS and SiPPS

The table compares features of conventional SPPS and SiPPS as reported in the evidence. No other comparative data were provided.

Enzymatic stability of modified LL-37

The modification of LL-37 with 2,3-diaminopropionic acid and an oxa-acid spacer was associated with enhanced enzymatic stability. This was observed in in vitro assays, where the modified peptides resisted proteolysis better than the native peptide [1]. The evidence block does not specify the enzymes used or the exact conditions.

Neutrophil degranulation and LL-37 modifications

In the same study, the modified LL-37 peptides selectively suppressed neutrophil degranulation. This effect was observed in in vitro experiments with human neutrophils. The native LL-37 has immunomodulatory functions, and the modification shifted the functional profile towards suppression of degranulation while maintaining antimicrobial activity [1]. No animal or human data were reported.

D-Amino acid-containing peptides and proteolytic resistance

The review on FDA-approved drugs containing D-amino acids reported that D-amino acids confer resistance to proteolytic degradation, enhanced conformational rigidity, and reduced immunogenicity. These properties have been exploited in peptide drug development to create long-acting peptides [2]. The evidence block does not provide specific examples or quantitative data.

Silica resin and coupling efficiency

In the SiPPS study, the use of a non-swelling silica-based resin was investigated. The researchers noted that a 2-hour coupling seemed to favour the coupling compared to a 1-hour standard coupling. The non-swelling nature of the resin may offer advantages in synthesis, but the evidence block does not elaborate on the yield or purity [3]. This was a laboratory-based study.

If you are reading this for personal health reasons

The materials and methods described here are sold for laboratory research only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Building Blocks of 2,3-Diaminopropionic Acid Functionalized with an Oxa-Acid Spacer Shift the Functional Profile of Human Cathelicidin LL-37: Enhanced Enzymatic Stability and Selective Suppression of Neutrophil Degranulation
• [2] FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective
• [3] Silica-Assisted Solid-Phase Peptide Synthesis (SiPPS)